We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Sleep Apnea Treatment Drives Respiratory Market Growth

By HospiMedica International staff writers
Posted on 16 Feb 2015
Of all respiratory treatments, the fastest growing market segment through 2018 will be devices used for the treatment of sleep apnea. More...
These are the latest findings of Kalorama Information (New York, NY, USA), an independent medical market research firm.

Sleep apnea is a condition of chronic airway obstruction during sleep, potentially leading to high blood pressure, cardiovascular disease, memory problems, weight gain, impotence, and headaches. The major underlying mechanisms or causes of sleep apnea include obstructive sleep apnea (OSA, the most common form of sleep apnea), frequently found in obese and aged individuals with low muscle tone and excessive soft tissue around the airway; central apnea, an imbalance in the brain’s respiratory control center that leads to a delayed neurological response to carbon dioxide (CO2) blood levels; and mixed apnea, a combination of central apnea and OSA.

The majority of the sleep apnea device market is served by continuous positive airway pressure (CPAP) systems, which consist of a flow generator that feeds a constant, controllable air pressure into the patient’s airway via a hose and mask over the nose. Some CPAP devices reduce air pressure upon exhalation to increase patient comfort, though such a feature is standard with bi-level positive airway pressure (PAP) systems intended for more sleep-sensitive patients or those with other respiratory issues. Automatic PAP (APAP) systems continuously adjust air pressure to accommodate variable patient breathing and reduce resistive pressure during exhalation.

“Respiratory health in populations worldwide has been challenged by numerous factors including worsening air quality, substandard living conditions, other allergenic risk factors, and even economic development,” concluded report author Kalorama analyst Mary Anne Crandall. “Asthma and chronic obstructive pulmonary disorder (COPD) have been significant factors fueling contemporary market growth.”

Over 20 million North American individuals are believed to suffer from sleep apnea, and there may be 30 million individuals in Europe and 220 million in the Asia-Pacific with the condition. This rate of prevalence is not surprising, given the risk factors, such as age, body weight, diabetes, and smoking. Among men aged 30-60 years old in the United States, the overall prevalence of sleep apnea is estimated at 9%–24%, but sleep apnea prevalence in diabetics is estimated at almost 50%, 77% for obese individuals, and 87% among obese individuals with type 2 diabetes.

Related Links:

Kalorama Information



Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Syringes
Prefilled Saline Flush Syringes
Digital Color Doppler Ultrasound System
MS22Plus
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.